



NDA 209092/S-009
NDA 209935/S-013

SUPPLEMENT APPROVAL

Novartis Pharmaceuticals Corporation
Attention: Colin Vechery, PharmD
Senior Manager, Regulatory Affairs
One Health Plaza
East Hanover, NJ 07936-1080

Dear Dr. Vechery:

Please refer to your supplemental new drug applications (sNDAs) and their amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA):

NDA 209092/S-009 dated March 16, 2021, received March 16, 2021, for
Kisqali (ribociclib) tablets

NDA 209935/S-013 dated March 17, 2021, received March 17, 2021, for
Kisqali/Femara Co-pack (ribociclib tablets in combination with letrozole tablets)

This sNDA provides for revisions to the US Prescribing Information (USPI) Section 5 Warnings and Precautions Subsection 5.3 QT Interval Prolongation, Section 6 Adverse Reactions Subsection 6.1 Clinical Trials Experience, and Section 13 Nonclinical Toxicology Subsection 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility with minor editorial revisions made throughout the USPI.

Prior Approval sNDA 209935/S-013 proposing the same updates as proposed in sNDA 209092/S-009 for Kisqali.

APPROVAL & LABELING

We have completed our review of this application. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at FDA.gov.¹ Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information, and Patient Package Insert), with the addition of any labeling changes in pending “Changes Being Effectuated” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*.²

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which the FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in Microsoft Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because none of these criteria apply to your application, you are exempt from this requirement.

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. For information about submitting promotional materials, see the final guidance for industry *Providing Regulatory Submissions in Electronic and Non-*

¹ <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>

² We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

*Electronic Format-Promotional Labeling and Advertising Materials for Human Prescription Drugs.*³

You must submit final promotional materials and Prescribing Information, accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form FDA 2253 is available at FDA.gov.⁴ Information and Instructions for completing the form can be found at FDA.gov.⁵

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, contact Kelly Chiang, Regulatory Project Manager, at Kelly.Chiang@fda.hhs.gov or 301-796-5822.

Sincerely,

{See appended electronic signature page}

Abhilasha Nair, M.D.
Associate Director for Safety (acting)
Office of Oncologic Diseases
Center for Drug Evaluation and Research

ENCLOSURE(S):

- Content of Labeling
 - Prescribing Information
 - Patient Package Insert

³ For the most recent version of a guidance, check the FDA guidance web page at

<https://www.fda.gov/media/128163/download>.

⁴ <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf>

⁵ <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf>

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

ABHILASHA NAIR
09/15/2021 12:04:36 PM